Published date:
24/01/2023
Summary:
• Two successful exits – Syndesi and BioPhero
• Four portfolio companies reported clinical data from first in class targets (Galecto, NMD Pharma, Heparegenix and MinervaX)
• Led three new seed investments and incubating additional projects
• Expanded team as part of strong investment in global talent to access innovation
• REPAIR Impact Fund making strides in the vital combat against Antimicrobial Resistance
Copenhagen, Denmark, 24 January 2023 – Seed Investments, the early stage investment and company creation team of Novo Holdings, today publishes its review of 2022 – delivering results in a challenging market.
